Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases

Abramson Cancer Center at Penn Medicine1 site in 1 country100 target enrollmentSeptember 10, 2015

ConditionsPancreatic Diseases

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Pancreatic Diseases
Sponsor: Abramson Cancer Center at Penn Medicine
Enrollment: 100
Locations: 1
Primary Endpoint: Collection of blood and tissue samples from subjects with pancreatic diseases
Status: Enrolling By Invitation
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to collect blood samples to detect potential markers of pancreatic cancer in the blood and link these findings to medical and health information. Information from this study may help to provide insight into the detection of pancreas cancer in the blood before it can be found by other methods or provide a method of monitoring the status of pancreatic cancer throughout a treatment course. Another purpose of this study is to collect blood to create a biobank.

Registry

clinicaltrials.gov

Start Date

September 10, 2015

End Date

January 1, 2035

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Abramson Cancer Center at Penn Medicine

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The subject must be a patient at the Hospital of the University of Pennsylvania
•The subject must be under evaluation and/or treatment for a pancreatic disease
•The subject must be under evaluation and/or treatment for a non-pancreatic disease. For example, patients undergoing routine colonoscopy within the clinical practice will be asked to consent to provide control samples.
•The subject must be able to provide informed consent or have an acceptable surrogate capable of giving consent on the subject's behalf
•The subject must be 18 years of age or older